Intracranial hypertension induced by rofecoxib

Saiju Jacob, Yusuf A Rajabally

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Several secondary causes are implicated in the etiology of idiopathic intracranial hypertension. Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor, now being increasingly used in place of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). We report a case of intracranial hypertension in a 69-year-old man 3 weeks after the commencement of rofecoxib therapy with reversal of clinical findings on drug withdrawal.

Original languageEnglish
Pages (from-to)75-6
Number of pages2
Issue number1
Publication statusPublished - Jan 2005


  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal/adverse effects
  • Arthritis, Rheumatoid/drug therapy
  • Cyclooxygenase Inhibitors/adverse effects
  • Humans
  • Intracranial Hypertension/chemically induced
  • Lactones/adverse effects
  • Male
  • Sulfones/adverse effects


Dive into the research topics of 'Intracranial hypertension induced by rofecoxib'. Together they form a unique fingerprint.

Cite this